Safety study of flash radiation for skin lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a new type of very-fast radiation therapy (called FLASH) is safe for treating cutaneous lymphoma—a cancer affecting the skin. The goal is to see if this faster treatment approach works well and causes fewer side effects than standard radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of cutaneous lymphoma (skin lymphoma confirmed by biopsy)
- Your lymphoma is located on an arm or leg and the lesion is no bigger than 7.5 cm across
- You have not had radiation therapy to this spot before
- You are willing to stop using topical creams or medications (including steroids) on the lesion for 4 weeks before treatment
- You are at least 18 years old and able to give informed consent or have someone who can consent for you
- You are in good enough health to tolerate the radiation treatment (ECOG score below 3)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of ultra-fast radiation called Flash radiotherapy to treat certain skin cancers. It is designed for patients who are at least 60 years old and cannot have surgery or choose not to have it.
This trial tests a new type of radiation therapy called ConformalFLASH that delivers radiation extremely quickly to treat head and neck cancer that has come back after previous radiation. It may help patients who cannot have surgery or have declined it.
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
This trial studies mogamulizumab (an antibody medicine) plus total skin electron beam therapy (whole-skin radiation) to treat cutaneous T-cell lymphoma. It may help by improving skin symptoms and controlling the lymphoma after prior treatments.
Hear when a new Cutaneous Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.